This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel obstruction.
18-75 years of age;
ECOG PS ≤3;
pathologically diagnosed gastric or gastroesophageal junctional adenocarcinoma;
peritoneal carcinomatosis established by imaging data or pathological evidence;
treated by a combination regimen containing all the study drugs;
allergy to any of the study drugs;
HER-2 amplification or overexpression, mismatch repair protein expression deletion (dMMR), or genetic testing suggestive of high microsatellite instability (MSI-H);
strangulated intestinal obstruction;
Sixth Affiliated Hospital, Sun Yat-sen University
Lead sponsor
Guangdong Provincial People's Hospital
Sponsor institution
Guangdong Provincial People's Hospital
Collaborator